

Amendments to the Claims under 37 C.F.R. § 1.121

Claim 1 (previously presented): A trimeric polypeptide comprising three monomers, wherein a first portion of each monomer comprises TNFRSF1A, TNFRSF1B, LTBR, TNFRSF4, TNFRSF5, TNFRSF6, TNFRSF6B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11 B, TNFRSF12, TNFRSF12L, TNFRSF13B, TNFRSF13C, TNFRSF14, NGFR, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF19L, TNFRSF21, TNFRSF22, or TNFRSF23, and a second portion of each monomer is a tetranectin trimerising structural element comprising an amino acid sequence having at least 87% identity with the amino acid sequence of SEQ ID NO:81.

Claims 2-18 (cancelled).

Claim 19 (previously presented): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising structural element comprises an amino acid sequence having at least 92% identity with the amino acid sequence of SEQ ID NO:81.

Claim 20 (previously presented): The trimeric polypeptide according to claim 1, wherein the tetranectin trimerising structural element comprises the amino acid sequence of SEQ ID NO:81.

Claim 21 (cancelled).

Claim 22 (previously presented): The trimeric polypeptide according to claim 1, further comprising a linker between the portion of each monomer that specifically binds a trimeric cytokine and the tetranectin trimerising structural element.

Claim 23 (previously presented): A pharmaceutical composition comprising the trimeric polypeptide according to claim 1.

Claims 24-29 (cancelled).

Claim 30 (previously presented): A method of preparing a pharmaceutical composition comprising combining the trimeric polypeptide according to claim 1 with a pharmaceutically acceptable carrier.

Claims 31-34 (cancelled).

Claim 35 (previously presented): The trimeric polypeptide according to claim 20, wherein the cysteine residue at position number 50 of the amino acid sequence of SEQ ID NO:81 is substituted with a serine, threonine, methionine, or any other amino acid residue.